SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer and infectious diseases,
today announced it will hold a conference call on November 2, 2020 at 1:30
p.m. Pacific / 4:30 p.m.
Eastern.
Dr. Amit Kumar, Anixa's Chief
Executive Officer, will provide an update on the status of the
Company's programs, including the impending filing of an
Investigational New Drug (IND) application for its breast cancer
vaccine, being developed with the Cleveland Clinic, the progress
with its CAR-T treatment for ovarian cancer, being developed with
the Moffitt Cancer Center, and the latest discoveries with its
Covid-19 therapy.
Conference Call Information:
Interested participants
and investors may access the conference call by dialing:
- (877) 876-9174
- Conference ID: Anixa
An audio webcast will be accessible via the Investors section of
the Anixa website at https://ir.anixa.com/events. An archive
of the webcast will remain available for 30 days after the
call.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company developing a number of
programs addressing cancer and infectious disease. Anixa's
therapeutic portfolio includes a cancer immunotherapy program which
uses a novel type of CAR-T, known as chimeric endocrine receptor
T-cell (CER-T) technology, and a Covid-19 therapeutics program
focused on inhibiting certain viral protein function. The
company's vaccine portfolio consists of a technology focused on the
immunization against α-Lactalbumin to prevent triple negative
breast cancer (TNBC). Anixa continually examines emerging
technologies in complementary fields for further development and
commercialization. Additional information is available at
www.anixa.com.
Forward-Looking Statements: Statements that
are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, the
timing of the impending filing of an IND application for the breast
cancer vaccine we are working on with the Cleveland Clinic, as well
as those factors set forth in "Item 1A - Risk Factors" and other
sections of our most recent Annual Report on Form 10-K as well as
in our Quarterly Reports on Form 10-Q and Current Reports on Form
8-K. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law. You are cautioned not to unduly rely on such
forward-looking statements when evaluating the information
presented in this press release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
mmiller@tiberend.com
212-375-2694
Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-to-host-conference-call-to-provide-update-on-programs-301160333.html
SOURCE Anixa Biosciences, Inc.